Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Tufts Medical Center
Study ID
NCT07473713
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Osteopenia

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • veverimer daily — DRUG
    8 weeks of taking 9 grams of veverimer (a powder mixed into water) daily
  • veverimer every other day — DRUG
    8 weeks of taking 9 grams of veverimer (a powder mixed into water) every other day
  • Placebo — OTHER
    8 weeks taking 9 grams microcrystalline cellulose (powdered mixed into water) daily or every other day

Study Details

The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug

Key Dates

Start date
Apr 15, 2026
Status verified
Mar 2026
Primary completion
Mar 1, 2028
Completion
May 1, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Veverimer 9 g/day
  • Experimental: Veverimer 9 g/every other day
  • Placebo Comparator: Placebo (microcrystalline cellulose with 0.075% yellow ferric oxide)

Primary Outcome Measure

24-hr urinary net acid excretion [ Time Frame: measured at screening, week 2, week 8 and week 8 +1day ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Tufts Medical CenterBostonMassachusetts02111
Elise Danico
[email protected]
617-636-3273
Lisa Ceglia, MD MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Tufts Medical Center· Boston, MA

Related Studies